Zydus Lifesciences reported its Q2 FY26 results, revealing a ₹12,586 million net profit. The company’s performance was bolstered by strong dividend income from subsidiaries, reaching ₹4,198 million. Total income for the quarter stood at ₹62,322 million. The Board approved these results on November 6, 2025. The financial results and limited review reports are available on Zydus’ website.
Financial Performance
Zydus Lifesciences announced its Q2 FY26 results, posting a net profit of ₹12,586 million. Total income for the quarter reached ₹62,322 million. Expenditure amounted to ₹45,106 million, with a significant contribution from the cost of materials consumed at ₹13,271 million.
Dividend and Other Income
Other income played a pivotal role, particularly dividend income from subsidiaries and joint ventures, contributing ₹4,198 million during the quarter. The company’s Q2 FY25 dividend income was ₹2,183 million. This increase significantly boosted overall profitability.
Segment Performance
The company operates with two business segments. The Pharmaceuticals segment generated a revenue of ₹54,743 million, with Consumer Products contributing ₹6,489 million. The Pharmaceuticals segment reported a profit before tax of ₹17,388 million, while Consumer Products saw a ₹172 million loss.
Board Meeting Outcome
The Board of Directors approved the unaudited financial results for Q2 FY26 on November 6, 2025. This decision was based on the recommendations of the Audit Committee, and the company has ensured compliance with relevant regulations for financial disclosures. The trading window will reopen on November 10, 2025.
Source: BSE
